Form 8-K Regulus Therapeutics For: Jan 27
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/18/2026
- Wall St ends lower for the day and week as chip selloff broadens
- Netflix earnings forecast disappoints Wall Street, shares tumble
- HSBC upgrades Apple to Buy, sees "strong cycle ahead"
- Kimi K3 AI breakthrough: What Wall Street analysts say about China’s OpenAI threat
- Why the Fed may still need to hike rates
- Assassin's Creed Black Flag Resynced sells 3M copies in a week
- Magnitude 7.4 earthquake strikes coast of Chiapas, Mexico; Tsunami waves are possible
- Magnitude 7.4 earthquake strikes Puerto Madero, Mexico, USGS says
- Adobe has received a takeover approach by a Big Tech company - Betaville
- Wall St ends lower for the day and week as chip selloff broadens
Needham & Company Downgrades Regulus Therapeutics (RGLS) to Hold
January 30, 2017 7:28 AM ESTNeedham & Company downgraded Regulus Therapeutics (NASDAQ: RGLS) from Buy to Hold.
Analyst Alan Carr commented, "RGLS announced late Friday that FDA has extended RG-101 clinical hold and requested additional long-term clinical data from ongoing trials. These data are not expected until 4Q17.... More
